Navigation Links
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Date:10/22/2008

somnia and a history of prolonged middle of the night awakenings. Subjects were randomized to receive 1.75 mg or 3.5 mg doses of Intermezzo(R), or a placebo, over three 2-night treatment periods.

The study results demonstrated that Intermezzo(R) 1.75 mg and 3.5 mg doses, when taken at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo and there was no evidence of next morning residual effects. Patients taking Intermezzo(R) 3.5 mg also had statistically significant improvements in post-dose total sleep time, sleep efficiency, subjective number of awakenings and sleep quality. Morning questionnaires also revealed improvements in the level of refreshed sleep and next day ability to function compared to placebo.

Dr. Roth commented, "This study supports the safety and efficacy of Intermezzo(R) for the treatment of middle of the night awakenings at the time they occur. The most commonly prescribed sleep medications are intended to be taken at bedtime and they produce sleep for seven to eight hours after dosing. Such medications can be used at bedtime to prevent an awakening later in the night, but the patient must either anticipate which nights an awakening may occur, or take a seven to eight hour sleep aid every night. The results of this study suggest that low dose sublingual zolpidem (Intermezzo(R)) may offer patients a fast acting low-dose alternative that can be taken only when it is really needed at the time of an awakening, and which provides rapid return to sleep without the risk of residual sedation the following morning."

Glenn A. Oclassen, President and Chief Executive Officer of Transcept, remarked, "We congratulate Dr. Roth and his colleagues on the publication in SLEEP. Along with our Phase 3 outpatient study, Dr. Roth's sleep-lab study serves as the foundation for the Intermezzo(R) New Drug Application we recently submitted to the U.S. Food and Drug Admini
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has commenced an underwritten public offering of its ... underwriters a 30-day option to purchase up to an ... offered in the public offering. The offering is subject ... as to whether or when the offering may be ...
(Date:4/30/2015)... Budapest, Hungary (PRWEB) April 30, 2015 ... electronic lab notebook with integrated protocols and specimen ... chemistry software solutions and consulting services for life ... the development of Labguru’s newest feature: chemical structure ... deep domain features for biologists, bio-chemists, and more, ...
(Date:4/30/2015)... -- - Continued Advancement Toward Goal ... Shire (LSE: SHP, NASDAQ: SHPG ) ... 31, 2015. Financial Highlights Q1 2015 ... revenues $1,488 million +11% +15% Non GAAP operating income ... continuing operations $475 million +55% Non GAAP EBITDA margin ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29
... and other rhetoric given by spokespeople from the incumbent telephone ... we should be asking this simple question: "Are they delivering ... , ,What speed are you really running at on your ... T-1 for a full T-1 price? These would seem to ...
... biotechnology hot spot will be further enhanced next ... one of the world's premier biotechnology conferences, businesses ... make up 1.5 percent of the total participation ... will be held April 9-12 at Chicago's McCormick ...
... edition, we interviewed Barry Chaiken, chair of the Digital Healthcare ... of BearingPoint. , , WTN: If I'm a hospital ... technology resources now? , , Barry Chaiken, MD ... money that I'm spending? Value is on two levels. One ...
Cached Biology Technology:Are speedometers for high-speed Internet service a new must-have? 2Are speedometers for high-speed Internet service a new must-have? 3Wisconsin to show up at BIO in numbers 2Wisconsin to show up at BIO in numbers 3Interview: Dr. Barry Chaiken on healthcare IT 2Interview: Dr. Barry Chaiken on healthcare IT 3
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... especially in rural areas, may interfere not only with ... finding flowers, according to researchers from Penn State and ... to perniciously alter key interactions between plants and animals," ... Environmental Research Letters . The animal tested in this ...
... than a thumbtack are being credited for playing a ... kinds of seafood, according to a new study by ... Survey. The little crustacean "grazers," some resembling tiny ... algae, helping keep these aquatic havens healthy for native ...
... ANALYTICS Device has ORNL pedigree . . . ... have an instrument that could accelerate drug discovery, aid ... hundreds of tests. The flowprobe system, which is based ... ORNL,s Chemical Sciences Division, allows for efficient, automated direct ...
Cached Biology News:Ozone masks plants volatiles, plant eating insects confused 2Tiny grazers play key role in marine ecosystem health 2April 2013 story tips 2April 2013 story tips 3
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Recombinant Mouse sTNF RII/TNFRSF1B...
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
Biology Products: